ERIS Lifesciences Ltd: Q2FY27 results
ERIS Lifesciences Ltd reported revenue of Rs 892 cr and net profit of Rs 187 cr for Q2FY27.
Filed 26 Oct 2026, 13:49 IST · ERIS Lifesciences Ltd (ERIS)
Price around the results
What was reported
ERIS Lifesciences Ltd reported revenue of Rs 892 cr and net profit of Rs 187 cr for Q2FY27. Figures are consolidated.
How it compares
Revenue changed +12.61% from a year earlier. Against the previous quarter revenue changed +2.19%.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹892 cr | ₹873 cr | +2.19% | +12.61% |
| Other income | ₹-34 cr | ₹2 cr | — | — |
| Expenses | ₹583 cr | ₹577 cr | +1.04% | +15.63% |
| Operating profit | ₹309 cr | ₹296 cr | +4.43% | +7.33% |
| Operating margin (%) | 34.67% | 33.92% | — | — |
| Interest | ₹46 cr | ₹47 cr | -0.49% | -6.32% |
| Depreciation | ₹73 cr | ₹72 cr | +1.87% | +6.28% |
| Profit before tax | ₹156 cr | ₹179 cr | -13.14% | -9.71% |
| Tax | ₹-31 cr | ₹36 cr | — | — |
| Net profit | ₹187 cr | ₹143 cr | +30.57% | +39.17% |
| EPS (₹) | ₹13.26 | ₹10.28 | +28.99% | +50.34% |
Operating margin of 34.67% compares with a Healthcare sector median of 23.41% across 7 peers that have reported Q2FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +0.41% | -0.27% |
Volume on the results session was 3.44× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Swiss Parenterals’ base business was largely uninterrupted in Q2.
Guidance & outlook
- Further gross margin gain is expected from the out-licensed portfolio.
- A full manufacturing shift to Bhopal is expected in the second half of next year.
Expansion
- The Bhopal facility has been commercialized, with vials and cartridges now in production.
- Swiss Parenterals’ New Unit III block is under construction, with PV batches planned by April 2027.
- New Unit III is planned to include PFS, vials, lyophilized products and cartridges, including dual-chamber cartridges.
New initiatives
- Three more analogs are entering the regulatory pathway between December and March of this financial year.
Competition
- Eris outgrew the market across all major therapies in Q2.
- Ex-Zorvia Eris growth was 17% in Q2 FY27.